Skip to main content
. 2014 Nov 11;1(1):80–89. doi: 10.1016/j.ebiom.2014.11.001

Fig. 2.

Fig. 2

Glucose homeostasis in MES + HS-treated MS or T2DM subjects. (A) Glucose excursions on 75 g oral glucose tolerance test (OGTT) in MS subjects (n = 40) after no treatment (open diamonds with solid line) or MES + HS treatment (closed squares with dotted line) period. (B) Serum insulin response on 75 g OGTT in MS after no treatment or MES + HS treatment period. (C) Glucose excursions on 592 kcal of meal tolerance test (MTT) in T2DM patients (n = 40) after no treatment or MES + HS treatment period. (D) The ratio of HbA1c less than 7.0% in T2DM patients without MES + HS (MES + HS(−)) or with MES + HS treatment period (MES + HS(+)). (E) Reductions in HbA1c sorted by pre-HbA1c levels upon MES + HS treatment. Sequential changes were analyzed by repeated-measures ANOVA, and the differences at each time point were analyzed by unpaired t-test. *p < 0.05, **p < 0.01.